^
Association details:
Biomarker:No biomarker
Cancer:Ovarian Cancer
Drug:Avzivi (bevacizumab-tnjn) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
12/06/2023
Excerpt:
Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of:…Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
Secondary therapy:
paclitaxel; pegylated liposomal doxorubicin; topotecan